A Pilot Study of Imetelstat given Intravenously on Day 1 and 8 of a 21 Day Scheudule Alone and With Standard 13Cis-Retinoic Acid in Children with Recurrent and/or Refractory Neuroblastoma

Trial Profile

A Pilot Study of Imetelstat given Intravenously on Day 1 and 8 of a 21 Day Scheudule Alone and With Standard 13Cis-Retinoic Acid in Children with Recurrent and/or Refractory Neuroblastoma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Imetelstat (Primary) ; Isotretinoin
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 02 Aug 2013 Planned number of patients (18) added as reported by ClinicalTrials.gov.
    • 02 Aug 2013 Planned end date (1 Apr 2016) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top